Premium
Syntheses and evaluation of 68 Ga‐ and 153 Sm‐labeled DOTA ‐conjugated bisphosphonate ligand for potential use in detection of skeletal metastases and management of pain arising from skeletal metastases
Author(s) -
Chakraborty Sudipta,
Goswami Dibakar,
Chakravarty Rubel,
Mohammed Sahiralam Khan,
Sarma Haladhar Deb,
Dash Ashutosh
Publication year - 2018
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13327
Subject(s) - dota , biodistribution , chemistry , ligand (biochemistry) , in vitro , bisphosphonate , conjugate , chelation , nuclear medicine , radiochemistry , medicine , biochemistry , receptor , osteoporosis , mathematical analysis , mathematics , organic chemistry
This article reports the syntheses and evaluation of 68 Ga‐ and 153 Sm‐complexes of a new DOTA (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetraacetic acid)‐conjugated geminal bisphosphonate, DOTA ‐Bn‐ SCN ‐ BP , for their potential uses in the early detection of skeletal metastases by imaging and palliation of pain arising from skeletal metastases, respectively. The conjugate was synthesized in high purity following an easily adaptable three‐step reaction scheme. Gallium‐68‐ and 153 Sm‐complexes were prepared in high yield (>98%) and showed excellent in vitro stability in phosphate‐buffered saline ( PBS ) and human serum. Both the complexes showed high affinity for hydroxyapatite particles in in vitro binding study. In biodistribution studies carried out in normal Wistar rats, both the complexes exhibited rapid skeletal accumulation with almost no retention in any other major organ. The newly synthesized molecule DOTA ‐Bn‐ SCN ‐ BP would therefore be a promising targeting ligand for the development of radiopharmaceuticals for both imaging skeletal metastases and palliation of pain arising out of it in patients with cancer when radiolabeled with 68 Ga and 153 Sm, respectively. A systematic comparative evaluation, however, showed that there was no significant improvement of skeletal accumulation of the 153 Sm‐ DOTA ‐Bn‐ SCN ‐ BP complex over 153 Sm‐ DOTMP (1,4,7,10‐tetraazacyclododecane‐1,4,7,10‐tetramethylenephosphonic acid) as the later itself demonstrated optimal properties required for an agent for bone pain palliation.